Gilead's Lenacapavir: Twice-Yearly HIV PrEP Could Be a $5B Product

Gilead Sciences already dominates HIV treatment with Biktarvy and Descovy. Lenacapavir (Yeztugo) is now making Gilead the leader in HIV prevention — a market that was barely tapped before approval.

The drug

Lenacapavir is a first-in-class capsid inhibitor — it targets the HIV capsid protein, disrupting multiple stages of the viral life cycle. It’s administered as a subcutaneous injection every six months.

For HIV PrEP (pre-exposure prophylaxis), lenacapavir is the first twice-yearly preventive option. Current PrEP alternatives require daily pills (Truvada, Descovy) or bimonthly injections (Apretude). A six-month injection solves the adherence problem that limits PrEP uptake.

The data

The Purpose 2 trial enrolled 3,200 participants at high risk of HIV infection. Results:

• 0 infections in the lenacapavir group (n = 2,184)
• Standard of care comparison: 99% relative risk reduction vs. background incidence
• Safety: No serious adverse events related to the drug

The Purpose 1 trial (announced in 2024) showed the same result: 0 infections in 2,134 women. Two trials, 5,300+ participants, 0 infections. The efficacy is unprecedented.

Approval and market

The FDA approved Yeztugo (lenacapavir) for PrEP on June 18, 2025, making it the first and only twice-yearly HIV prevention option. The approval was based on the Purpose 1 and Purpose 2 trials. Lenacapavir is also approved for treatment of multi-drug-resistant HIV in combination with other antiretrovirals.

Global PrEP uptake is low. Of the 1.2 million people who could benefit from PrEP in the US, only ~300,000 are on it. The barriers: daily pill fatigue, stigma, and access. A twice-yearly injection removes the adherence barrier. Peak PrEP sales estimates range from $3–5 billion globally.

Gilead is also running the STAR study to test lenacapavir as a twice-yearly treatment (not just prevention) for people who already have HIV. That’s a separate $5B+ opportunity.

The risk

The science is strong. The risk is commercial:

1. Pricing: Lenacapavir is expensive to manufacture. If Gilead prices it too high, access programs and generics manufacturers (in developing countries) could limit revenue.
2. Access: Gilead has committed to licensing lenacapavir to generic manufacturers for 120 low-income countries. This is good for public health but limits the revenue model. Several African countries (Mozambique, Namibia, Kenya, Uganda) and Brazil already approved lenacapavir for PrEP in January 2026.
3. Competition: ViiV Healthcare’s cabotegravir (Apretude) is a bimonthly PrEP injection. Lenacapavir’s twice-yearly dosing is better, but Apretude has a head start.

What we’re watching

1. BIC/LEN approved as Bixlenvo (August 27, 2026): Gilead’s NDA for a once-daily single-tablet regimen combining bictegravir with lenacapavir was approved August 27, 2026 as Bixlenvo — the first and only once-daily single-tablet regimen for virologically suppressed adults with HIV on complex regimens. See our Bixlenvo approval coverage.
2. Once-weekly oral lenacapavir (PDUFA February 2, 2027): Gilead has filed an sNDA for a 300-mg weekly oral formulation of Yeztugo for PrEP. If approved, this would be the first long-acting oral PrEP option.
3. Commercial uptake: Early prescription data for the twice-yearly injection will signal whether the convenience advantage is converting patients from daily PrEP.
4. Access deals: Gilead’s licensing agreements for developing countries will affect both public perception and revenue.

Gilead’s stock is up 4% YTD, and lenacapavir is a key growth story beyond the oncology portfolio. The HIV franchise isn’t going away — it’s evolving. For the longer arc, the HIV cure pipeline remains years from a Phase 3 readout.

What It Means for the Trade

The twice-yearly injection is the franchise anchor, but the near-term catalysts are both oral: Bixlenvo (approved August 27) extends lenacapavir into once-daily treatment, and the February 2, 2027 PDUFA for weekly oral Yeztugo could make lenacapavir the first long-acting oral PrEP. That sequencing matters for the trade — the $3-5 billion PrEP peak-sales estimates assume the adherence barrier falls, and a weekly pill removes it for the pill-preferring majority who will never accept an injection. The commercial gating factor is conversion: only ~300,000 of 1.2 million eligible US patients are on any PrEP, so the bull case is market expansion rather than share capture from Truvada or Descovy. Apretude’s bimonthly injection never broke the market open; watch whether lenacapavir’s six-month interval does what a two-month interval could not. Pricing discipline is the other watch item — the 120-country generic licensing protects the access narrative but caps ex-US upside.

Mechanism and Market Context

Lenacapavir binds the HIV capsid, the protein shell protecting the virus’s genetic core, and disrupts it at multiple life-cycle stages — both blocking infection of new cells and interfering with capsid-mediated steps in established infection. No other approved drug works this way, and the potency-to-durability profile is what makes twice-yearly dosing pharmacologically possible at all. That is the strategic moat: Purpose 1 and Purpose 2 together showed zero infections across 5,300-plus participants, a standard no daily-pill regimen has ever matched in real-world adherence terms. The STAR study extends the molecule into twice-yearly treatment, and Bixlenvo’s bictegravir pairing folds lenacapavir back into Gilead’s core single-tablet-regimen playbook — evidence the company sees the capsid inhibitor as platform infrastructure, not a one-indication product.

Risks and What Could Go Wrong

1. The weekly oral PrEP PDUFA (February 2, 2027) is a binary; a CRL would undercut the oral-expansion narrative while the injection ramps.
2. Payer and access-program friction — lenacapavir is expensive to manufacture, and US pricing power collides with the public-health optics of prevention.
3. ViiV’s four-month cabotegravir formulation and the Gilead/Merck weekly oral ISL/LEN pill could crowd the same long-acting lane from both directions.